Thank you for contacting the Investment Industry Regulatory Organization of Canada (IIROC).
Primo Nutraceuticals Inc. has been subject to a Cease-trade Order (CTO) since December 4th, 2020, by the British Columbia Securities Commission (BCSC) and the Ontario Securities Commission (OSC) for failing to meet disclosure requirements- See link below provided by the BCSC:
https://www.bcsc.bc.ca/-/media/PWS/New-Resources/Decision-and-Orders/Cease-Trade-Orders/2020/2020-BCSECCOM-490.pdf
Further to point #8 of the CTO, if you are attempting to sell shares that you already own, you should contact the compliance department of the investment dealer that you hold your shares with to discuss the possibility of being able to sell your shares on a foreign organized regulated market (FORM).
Additional information/news regarding this issuer can be found on SEDAR. SEDAR (the System for Electronic Document Analysis and Retrieval) is the system used by Issuers for electronically filing most securities related information with the Canadian securities regulatory authorities.
For more information on IIROC’s Policy on Halts and Most Recent Announcements, please visit our website at www.iiroc.ca.
For further queries relating to this CTO, you should consider contacting:
British Columbia Securities Commission
Telephone: 1-800-373-6393
Email: inquiries@bcsc.b.ca
Primo Nutraceuticals Inc.
Contact Name: Amandip Jagpal
Telephone: 844-734-8420
Email: andyjagpal@hotmail.com
Regards,
Georges Ahmar
Senior Complaints & Inquiries Specialist
Investment Industry Regulatory Organization of Canada
Spcialiste Snior de Plaintes et Renseignements
Organisme Canadien de Rglementation du Commerce des Valeurs Mobilires
OCRCVM/IIROC
525, avenue Viger Ouest
Bureau 601
Montral (Qubec)
H2Z 0B2
T: 1-877-442-4322
F: 1-888-497-6172
Protecting Investors and Supporting Healthy Canadian Capital Markets.
Protger les investisseurs et favoriser des marchs financiers sains au Canada.
This message is intended only for the use of the intended recipients, and it may contain information that is privileged and confidential. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, such reader is hereby notified that any review, retransmission, conversion to hard copy, copying, circulation or other use of this message is strictly prohibited and may be illegal. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. Thank you.
Le prsent message s'adresse uniquement au(x) destinataire(s) envisag(s) et peut renfermer des renseignements privilgis et confidentiels. Si le lecteur de ce message n'est pas le destinataire envisag, ou s'il n'est pas un employ ou un mandataire charg de remettre ce message au destinataire envisag, le lecteur est par les prsentes mis en garde contre le fait que l'examen, la retransmission, le transfert sur support papier, la copie, la diffusion ou toute autre utilisation de ce message est formellement interdit et peut tre illgal. Si cette communication vous a t transmise par erreur, veuillez nous en aviser immdiatement en y rpondant, puis supprimez le message de votre ordinateur. Merci
De : fred lawrence <gunman300@yahoo.ca>
Envoy : March 2, 2021 12:31 PM
: Investor Inquiries <InvestorInquiries@IIROC.CA>
Objet : Primo Nutraceuticals.
[EXTERNAL EMAIL / COURRIEL EXTERNE]
[EXTERNAL EMAIL / COURRIEL EXTERNE]